Clinical Trial News

Psilocybin Shows Promise in Reducing Depression and Anxiety in Cancer Patients

9 years ago

A study conducted by Johns Hopkins University School of Medicine found that a high dose of psilocybin, administered under supportive conditions, significantly decreased symptoms of depression and anxiety in cancer patients. These effects were sustained for up to six months, with participants reporting improved quality of life and decreased death anxiety.

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595CompletedPhase 2

Johns Hopkins University

Posted 4/1/2007

NICE Proposes Three-Tier Cost-Effectiveness Framework for Drug Evaluation in UK

9 years ago

NICE has established a three-threshold system for drug cost-effectiveness, ranging from £20,000-30,000 per QALY for common diseases to £100,000 for ultra-orphan drugs.
End-of-life treatments receive special consideration with a higher threshold of approximately £50,000 per QALY, reflecting society's prioritization of terminal care.
The new £100,000 per QALY threshold for ultra-orphan drugs has sparked debate about evidence-based decision making and resource allocation in healthcare.

FDA Approves Rival Diabetes Combinations Xultophy and Soliqua for Type 2 Diabetes Management

9 years ago

The FDA has simultaneously approved two novel diabetes combination therapies: Novo Nordisk's Xultophy (insulin degludec/liraglutide) and Sanofi's Soliqua (insulin glargine/lixisenatide) for type 2 diabetes management.
Clinical trials demonstrated Xultophy's superior efficacy, with patients 4.5 times more likely to achieve glycemic targets without hypoglycemia compared to Lantus alone.
Both once-daily injectable combinations will enter the US market in early 2017, with Soliqua launching in January and Xultophy following in the first half of the year.

GSK's GSK5764227 Receives FDA Breakthrough Therapy Designation for Osteosarcoma

9 years ago

GSK5764227, a B7-H3-targeted antibody-drug conjugate, has been granted Breakthrough Therapy Designation by the FDA for osteosarcoma treatment.
The designation aims to accelerate the development and review of GSK5764227 for relapsed or refractory osteosarcoma in adults.
This is the third regulatory designation for GSK5764227, highlighting its potential in treating serious conditions with limited therapeutic options.
The FDA's decision is based on preliminary clinical evidence suggesting substantial improvement over existing therapies for bone cancer.

Teva and IBM Watson Partner to Accelerate AI-Driven Drug Repurposing Initiative

9 years ago

Teva Pharmaceuticals and IBM Watson Health have launched a collaborative project using artificial intelligence to identify new therapeutic applications for existing drug compounds.
The partnership leverages Watson's cognitive computing capabilities to analyze Teva's compound portfolio, with initial focus on developing abuse-deterrent opioids and extended-release schizophrenia treatments.
The collaboration extends to developing predictive models for chronic conditions like asthma, incorporating weather data to help prevent disease exacerbations through patient-centric digital solutions.

Kymab and EpimAb Form Strategic Alliance to Develop Novel Bispecific Antibodies for Cancer Treatment

9 years ago

UK-based Kymab partners with China's EpimAb Biotherapeutics, combining Kymouse antibody platform with FIT-Ig technology to develop innovative bispecific antibodies for immuno-oncology applications.
The collaboration grants Kymab development rights outside China while EpimAb retains rights within China, with both companies eligible for milestone payments and royalties.
The partnership aims to leverage Kymab's nine existing immuno-oncology projects and four therapeutic approaches, including NK- and T-cell activation and macrophage-mediated cancer cell destruction.

Nivolumab Shows Promise in Advanced Head and Neck Cancer Treatment

9 years ago

Nivolumab significantly extends survival in advanced head and neck cancer patients compared to chemotherapy, offering a new treatment option.
A clinical trial demonstrated that 36% of patients treated with nivolumab were alive after one year, versus 17% with chemotherapy.
Combination therapy of nivolumab and ipilimumab shows potential in reducing tumor size in advanced kidney cancer patients.
Immunotherapy, like nivolumab, harnesses the immune system to target and destroy cancer cells, with fewer side effects.

Ribociclib Shows Promise in Advanced Breast Cancer Treatment

9 years ago

Ribociclib, a CDK 4/6 inhibitor by Novartis, significantly improved progression-free survival when combined with letrozole in patients with hormone receptor-positive advanced breast cancer.
The MONALEESA-2 trial demonstrated a 63.0% progression-free survival rate at 18 months for ribociclib plus letrozole, compared to 42.2% with letrozole alone.
Common side effects of ribociclib include neutropenia, infection, hair loss, diarrhea, and nausea, with a small percentage of patients experiencing a prolonged QT interval.
Ribociclib's efficacy and potential high cost raise questions about its accessibility and how it compares to similar drugs like palbociclib.

Strategic Framework for Early Asset Development: Integrating Clinical, Patient, and Commercial Value

9 years ago

Early-stage pharmaceutical development faces significant challenges due to data gaps and evolving treatment landscapes, requiring teams to predict market conditions 5-10 years ahead.
Successful asset development demands integration of three key value streams: clinical feasibility, patient benefits, and commercial viability, with emphasis on evidence-based decision making.
Modern healthcare development increasingly prioritizes patient voice and real-world outcomes, while navigating an increasingly competitive reimbursement landscape with multiple approved therapies.

Verily Partners with Dutch Institutions to Launch Large-Scale Parkinson's Disease Study

9 years ago

Google's life sciences division Verily collaborates with Radboud University Medical Center and ParkinsonNet to study disease progression in 650 Parkinson's patients using advanced imaging and wearable technology.
The study aims to understand individual variations in Parkinson's disease progression and treatment response, potentially enabling more personalized treatment approaches for the 10 million affected globally.
Researchers will utilize real-time data collection through advanced brain imaging, molecular analysis, and wearable devices, with findings to be made freely available to Dutch hospitals and international researchers.